Clinical trial · Observational
Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer
Evaluating the Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer Patients: A Prospective Longitudinal Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A prospective longitudinal cohort study that will assess the effect of a Personalized Medicine (PM) clinic recommendations on pharmacogenetic variation and/or interacting drugs on plasma drug exposure, effectiveness or toxicity of commonly used antidepressant, pain, and antiemetic medications in cancer patients. Such recommendations will entail genotype-guided treatment suggestions while also considering potential DDI, and will be provided to patients during their clinic visit, and referring physicians thereafter. Drug concentration and therapeutic effectiveness will be assessed before (baseline) and 6 months after recommendations have been provided. To assess effectiveness, patient-reported outcomes will be evaluated using validated scales for symptoms of depression, pain and chemotherapy-induced nausea/ vomiting The investigators hypothesize that the pharmacogenetic variation and DDI, if applicable, determine steady state drug concentration and therapeutic response or toxicity of the investigated antidepressant, pain or antiemetic treatments at baseline, while there is a clinically significant reduction or absence of the effect 6 months after the PM clinic recommendations to referring physicians and patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Pain | — | UNRESOLVED | — |
| Depression, Reactive | — | UNRESOLVED | — |
| Nausea With Vomiting Chemotherapy-Induced | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Drug-Drug interaction analysis | Other | — | UNRESOLVED |
| Pharmacogenetic testing | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Anti-depressants
- description
- Patients who have been prescribed either 1) the selective serotonin reuptake inhibitors (SSRI) citalopram or escitalopram, or 2) the selective norepinephrine reuptake inhibitors (SNRI) venlafaxine or desvenlafaxine
- interventionNames
- Genetic: Pharmacogenetic testing
- Other: Drug-Drug interaction analysis
- label
- Opioid pain medications
- description
- Patients who have been prescribed opioid pain medications including codeine, oxycodone, hydrocodone, or tramadol.
- interventionNames
- Genetic: Pharmacogenetic testing
- Other: Drug-Drug interaction analysis
- label
- Anti-metics
- description
- Patients who have been prescribed the antiemetic agent ondansetron
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years or older * Prescribed a chemotherapy medication * Currently taking one or more study medications (citalopram, escitalopram, venlafaxine, desvenlafaxine, codeine, oxycodone, hydrocodone, tramadol or ondansetron) Exclusion Criteria: * Patients who are unable to complete study materials (surveys) with or without assistance, including non-English speaking patients * Patients receiving palliative care * Patients taking anti-depressants for reason other than depression or anxiety, i.e. hot flash (Only applies to antidepressant cohort) * Patients with preexisting major depressive disorder prior to cancer diagnosis (Only applies to antidepressant cohort)
References
Publications (0)
Data not yet available